Skip to main content
Equibles
PSNL logo

PSNL · Personalis, Inc. · Webcasts, Transcripts & Audio

Track PSNL — free

Use PSNL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PSNL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.98 +0.10 (+0.63%) At close · Oct 27 Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.70B
Shares
106.80M
Volume · Oct 27 1.83M Avg daily vol (3M) 2.78M

Personalis, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Personalis, Inc. (PSNL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-08-04
Personalis, Inc. (PSNL) Q2 2026 Earnings Call
Revenue
$22.36M
▲ 30% YoY
Diluted EPS
$-0.30
Gross margin
21.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Confident tone Clinical test volume growth and ordering physicians Reimbursement and Medicare submissions Biopharma MRD business and backlog
Revenue
$15.47M
▼ 24.9% YoY
Diluted EPS
$-0.29
Gross margin
1.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Confident tone Medicare reimbursement coverage MRD strategy and market opportunity Clinical test volume growth
Revenue
$17.34M*
▲ 3.2% YoY
Gross margin
11.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
Positive tone Medicare reimbursement and MolDX dossiers Clinical volume growth and physician adoption Clinical evidence and Phase III trial data
Revenue
$14.49M
▼ 43.6% YoY
Diluted EPS
$-0.24
Gross margin
13.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
Positive tone Reimbursement / Medicare Coverage Tempus Commercial Partnership MRD Clinical Adoption (NeXT Personal)
Revenue
$17.20M
▼ 23.8% YoY
Diluted EPS
$-0.23
Gross margin
27.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript
Confident tone MRD strategy and NeXT Personal adoption Quarterly financial results and cash position Reimbursement and Medicare submissions
Revenue
$20.61M
▲ 5.5% YoY
Diluted EPS
$-0.18
Gross margin
35.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-11-06
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
Confident tone NeXT Personal MRD product and clinical impact Reimbursement pursuit Tempus commercial partnership
Revenue
$25.71M
▲ 40.9% YoY
Diluted EPS
$-0.64
Gross margin
34.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript
Confident tone MRD / NeXT Personal Test Win-in-MRD Strategy and Pillars Biopharma Growth
Revenue
$22.58M
▲ 35.2% YoY
Diluted EPS
$-0.24
Gross margin
35.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript
Confident tone MRD strategy and NeXT Personal launch NeXT Dx / Tempus relationship Natera collaboration
Revenue
$19.52M
▲ 3.5% YoY
Diluted EPS
$-0.26
Gross margin
28.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
Confident tone Biopharma and enterprise partnerships Win-in-MRD strategy and NeXT Personal Clinical evidence and reimbursement
Revenue
$19.68M*
▲ 17.7% YoY
Gross margin
26.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript
Revenue
$18.25M
▲ 22.8% YoY
Diluted EPS
$-0.60
Gross margin
19.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Personalis, Inc. (PSNL) Q2 2023 Earnings Call Transcript
Revenue
$16.70M
▼ 8.4% YoY
Diluted EPS
$-0.50
Gross margin
28.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Personalis, Inc. (PSNL) Q1 2023 Earnings Call Transcript
Revenue
$18.86M
▲ 23.9% YoY
Diluted EPS
$-0.61
Gross margin
25.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Personalis, Inc. (PSNL) Q4 2022 Earnings Call Transcript
Revenue
$16.72M*
▼ 19.1% YoY
Gross margin
13.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Personalis, Inc. (PSNL) Q3 2022 Earnings Call Transcript
Revenue
$14.86M
▼ 33.3% YoY
Diluted EPS
$-0.58
Gross margin
16.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Personalis, Inc. (PSNL) Q2 2022 Earnings Call Transcript
Revenue
$18.24M
▼ 15.8% YoY
Diluted EPS
$-0.60
Gross margin
23.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Personalis, Inc. (PSNL) Q1 2022 Earnings Call Transcript
Revenue
$15.23M
▼ 27.1% YoY
Diluted EPS
$-0.63
Gross margin
28.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Personalis, Inc. (PSNL) Q4 2021 Earnings Call Transcript
Revenue
$20.68M*
▲ 2.5% YoY
Gross margin
38.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Personalis, Inc. (PSNL) Q3 2021 Earnings Call Transcript
Revenue
$22.26M
▲ 12.3% YoY
Diluted EPS
$-0.40
Gross margin
36.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Personalis, Inc. (PSNL) Q2 2021 Earnings Call Transcript
Revenue
$21.67M
▲ 11.2% YoY
Diluted EPS
$-0.34
Gross margin
37.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Personalis, Inc. (PSNL) Q1 2021 Earnings Call Transcript
Revenue
$20.88M
▲ 9% YoY
Gross margin
35.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Personalis, Inc. (PSNL) Q4 2020 Earnings Call Transcript
Revenue
$20.18M*
▲ 11.1% YoY
Gross margin
30.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Personalis, Inc. (PSNL) Q3 2020 Earnings Call Transcript
Revenue
$19.82M
▲ 15.5% YoY
Gross margin
26.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Personalis, Inc. (PSNL) Q2 2020 Earnings Call Transcript
Revenue
$19.50M
▲ 23.2% YoY
Gross margin
24.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Personalis, Inc. (PSNL) Q1 2020 Earnings Call Transcript
Revenue
$19.16M
▲ 36.1% YoY
Gross margin
21.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-25
Personalis, Inc. (PSNL) Q4 2019 Earnings Call
Revenue
$18.15M
▲ 38% YoY
Gross margin
36.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–26 of 26 webcasts
Key facts CIK 1527753 CUSIP 71535D106 13F (30d) 20 filings 20 filers Visit website Investor relations